Roche Holding Aktiengesellschaft operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Roche Holding Aktiengesellschaft with three other
pharmaceutical manufacturers in Europe:
Novartis AG
(2020
sales of 46.58 billion Swiss Francs [US$50.35 billion]
of which 78%
was Innovative Medicines),
GlaxoSmithKline plc
of UNITED KINGDOM
(£34.10 billion [US$46.65 billion]
of which 50%
was Pharmaceuticals), and
Bayer AG
which is
based in GERMANY
(41.40 billion Euros [US$48.48 billion]
of which 46%
was CropScience).
Sales Analysis.
Sales were up sharply during the second
quarter of 2021 versus the previous year's second quarter.
During the second
quarter of 2021, sales at Roche Holding Aktiengesellschaft totalled
30.71 billion Swiss Francs.
This is
an increase of 117.2%
from the 14.14 billion Swiss Francs in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Roche Holding Aktiengesellschaft in the previous 33 quarters.
During the first two
quarters of 2021, sales totalled 45.64 billion Swiss Francs, which is
55.9% higher
than through the first two quarters of 2020.
Roche Holding Aktiengesellschaft reported sales of 58.32 billion Swiss Francs (US$63.05 billion)
for the
year ending
December of 2020.
This
represents
a
decrease of 5.1%
versus 2019, when the company's sales were 61.47 billion Swiss Francs.
Contributing to the drop in overall sales was the 8.2% decline
in Pharmaceuticals, from 48.52 billion Swiss Francs to 44.53 billion Swiss Francs.
.
However, these declines were partially offset by the increase in sales of
Diagnostics (up 6.5% to 13.79 billion Swiss Francs)
.